SciHub
文献互助
期刊查询
一搜即达
科研导航
交流社区
登录
注册
发布
文献
求助
首页
我的求助
捐赠本站
w2503
Lv1
9
40 积分
2021-02-19 加入
最近求助
最近应助
互助留言
Establishment and validation of a sensitive LC–MS/MS method for the quantification of KRASG12C protein PROTAC molecule LC‐2 in rat plasma and its application to in vivo pharmacokinetic studies of LC‐2 PEGylated liposomes
13分钟前
已完结
RAS degraders: The new frontier for RAS-driven cancers
54分钟前
已完结
Progress in RAS‐targeted therapeutic strategies: From small molecule inhibitors to proteolysis targeting chimeras
58分钟前
已完结
237 InnovaTV 301/ENGOT-Cx12/GOG-3057: a global, randomized, open-label, phase 3 study of tisotumab vedotin versus investigator’s choice of chemotherapy in 2L Or 3L recurrent or metastatic cervical cancer
1天前
已完结
New ADCs bring new questions in EGFR NSCLC and beyond
1天前
已完结
360 Health-related quality of life in patients with FRα positive platinum-resistant ovarian cancer treated with mirvetuximab soravtansine vs. investigator’s choice chemotherapy: analysis from the phase 3 MIRASOL trial
1天前
已完结
1232 Evaluation of HER2 expression in low grade serous carcinoma of the ovary in the antibody-drug conjugate era
1天前
已完结
#168 UPLIFT (ENGOT-Ov67/GOG-3048): results from the phase 2 trial of upifitamab rilsodotin (UpRi; XMT-1536), a NaPi2b-directed dolaflexin antibody-drug conjugate (ADC) in platinum-resistant ovarian cancer (PROC)
1天前
已完结
Extravasation of brentuximab vedotin, an antibody-drug conjugate, in a patient with anaplastic large cell lymphoma
1天前
已完结
Antibody-drug conjugates in lung and breast cancer: Current evidence and future directions – a position statement from the ETOP IBCSG Partners Foundation
1天前
已完结
没有进行任何应助
感谢
12分钟前
感谢
53分钟前
感谢
54分钟前
感谢
19小时前
感谢
19小时前
感谢
19小时前
感谢
19小时前
感谢
19小时前
感谢
1天前
感谢
1天前
最近帖子
最近评论
没有发布任何帖子
没有发布任何评论